BridGene Biosciences, Inc., a biotechnology company using a unique chemoproteomic technology to discover and develop small molecules for high value, traditionally undruggable targets, announced today the titles of the abstracts accepted by the American Association for Cancer Research (AACR) for poster presentations during the 2021 AACR-NCI-EORTC Virtual International Conference.
| SAN JOSE, Calif., Sept. 30, 2021 /PRNewswire/ -- BridGene Biosciences, Inc., a biotechnology company using a unique chemoproteomic technology to discover and develop small molecules for high value, traditionally undruggable targets, announced today the titles of the abstracts accepted by the American Association for Cancer Research (AACR) for poster presentations during the 2021 AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics. BridGene submitted five abstracts detailing the company’s proprietary small molecule discovery platform, IMTAC™ (Isobaric Mass Tagged Affinity Characterization), BridGene’s latest discovery of therapeutic candidates, and the identification of new targets for approved small molecule drugs. The conference will take place virtually October 7–10, 2021.
The titles of the abstracts are currently available on the AACR web site, with full abstracts, including the dates and times of presentations, scheduled for publication at 9:00 a.m. ET on October 7, 2021. The titles of the presentations are as follows: Abstract Title: A chemoproteomic platform for identifying small-molecule modulators of protein-protein interactions, discovering new cancer targets, and revealing previously unknown targets for well-known drugs Abstract Title: Identification of previously unknown targets for approved small-molecule drugs using chemoproteomic platform IMTAC™ Abstract Title: Discovery of novel small-molecule inhibitors for an epigenetic modulator WDR5 Abstract Title: Discovery and development of novel covalent inhibitors of the YAP-TEAD transcription activity Abstract Title: Discovery of a covalent inhibitor for an oncogenic mutant RhoAY42C “We are excited to have all five of our abstracts accepted for poster presentations during this year’s AACR-NCI-EORTC, which is among the most prominent scientific gatherings addressing drug discovery and molecular targets,” stated Ping Cao, Ph.D., Co-Founder and CEO of BridGene Biosciences. “Our posters will illustrate how the work at BridGene has the potential to address multiple therapeutic areas and bring game-changing capabilities to drug discovery and development. Overall, the posters describe our IMTAC platform technology and its capabilities, the discovery of novel small molecule inhibitors for undruggable targets, and the identification of previously unknown targets for approved small molecule drugs. We look forward to having this opportunity to showcase the potential of BridGene’s technology.” Information about the 2021 AACR-NCI-EORTC conference may be accessed here. About AACR About BridGene Biosciences Contact Dave Schemelia (media)
SOURCE BridGene Biosciences |
View original content to download multimedia:
